Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial

BACKGROUND/OBJECTIVE: The survival benefit of treatment for unresectable hepatocellular carcinoma (HCC) with transcatheter arterial chemoembolization (TACE) combined with sorafenib remains uncertain. We compared the survival of patients treated with TACE and sorafenib with that of patients treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Teng-Yu, Lin, Chen-Chun, Chen, Chiung-Yu, Wang, Tsang-En, Lo, Gin-Ho, Chang, Chi-Sen, Chao, Yee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604624/
https://www.ncbi.nlm.nih.gov/pubmed/28906355
http://dx.doi.org/10.1097/MD.0000000000007655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604624/
https://www.ncbi.nlm.nih.gov/pubmed/28906355
http://dx.doi.org/10.1097/MD.0000000000007655

Ejemplares similares